Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2013
Reporting Period: Event date March 13, 2013; Signed March 18, 2013.
Context: The filing serves as a Regulation FD disclosure providing an update on the Company's clinical trial for the dermaPACE device, which is being investigated for the treatment of diabetic foot ulcers.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing is strictly an operational update regarding clinical trial progress.
Material Changes
Clinical Trial Update: The Company provided an update on its ongoing clinical trial for the dermaPACE device. Specific quantitative results or changes in trial status are detailed in the attached press release (Exhibit 99.1) rather than the body of this 8-K.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on March 13, 2013, for details on the clinical trial update.
Legal Disclaimer: The information contained in Item 7.01 and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Risks/Contingencies: No specific risks or contingencies are enumerated in the text of this 8-K; the primary focus is the disclosure of the clinical trial update.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 13, 2013) for specific details on the dermaPACE clinical trial results.
- Verify the current status of the diabetic foot ulcer treatment trial in subsequent filings or press releases.
- Check for any subsequent 10-Q or 10-K filings to obtain financial performance data, as this 8-K contains no financial metrics.